Macrogenics Financial Results
MacroGenics reported third quarter 2026 financial results, highlighting a cash position of $287.7 million and a cash runway extending through 2028. The company achieved several clinical milestones, including completing Phase 1 dose escalation for MGC028 and dosing the first patient in the Phase 1 study of MGC030.
- Term
- Q3 2026
“MacroGenics has made significant progress over the past year. We have strengthened our business, sharpened our pipeline development priorities, delivered on key strategic objectives and generated approximately $290 million in non-dilutive capital over the past 12 months.”
Eric Risser, President and Chief Executive Officer
“Looking ahead, we believe MacroGenics is well positioned for a year of important milestones in 2027, with multiple opportunities to demonstrate the potential of our innovative pipeline while maintaining a disciplined approach to capital allocation.”
Eric Risser, President and Chief Executive Officer